Purpose <p>Prognostic impact of left ventricular diastolic dysfunction (LVDD) in septic shock patients has not been determined using current diagnostic guidelines. We assessed the relation between LVDD during the first 3&#xa0;days following intensive care unit (ICU) admission for septic shock and Day-28 mortality.</p> Methods <p>This prospective, multicenter, observational study enrolled 402 patients (age: 63 ± 13&#xa0;year; 59% male; SAPS II: 59 ± 20; SOFA: 9.4 ± 3.6; mechanical ventilation: 74%) with septic shock (Sepsis-3 definition). Patients were echocardiographically assessed within 12&#xa0;h after admission (Day 1), on Day 2, Day 3, at ICU and at hospital discharge (or Day 28 whichever occurred first), using 2016 American-European guidelines.</p> Results <p>LVDD was present at least once between Day 1 and 3 in 304 patients (76%), and in 56% and 44% of patients at ICU discharge and on Day 28 (or hospital discharge), respectively (43% of patients with follow-up). Seventy-eight of 172 patients (45%) exhibited similar LV diastolic properties throughout the study period while 58 patients (34%) improved their LVDD at follow-up (lower grade: n = 9, regression: n = 49). Day-28 mortality was not statistically different between patients with and without LVDD (80/304 [26%] vs. 25/88 [28%]; OR: 0.900 [0.530–1.527]; p = 0.696). Similar results were obtained when adjusting the multivariate model on SAPSII or SOFA score on admission, together with fluid balance during the first three days of ICU stay (OR: 0.838 [0.471–1.491]: p = 0.547 and OR: 0.887 [0.513–1.534]: p = 0.668, respectively).</p> Conclusion <p>LVDD was highly prevalent in patients with septic shock but not associated with mortality. It appeared improving in one-third of survivors.</p> Trial registration <p>PRODIASYS study registered on ClinicalTrials (September 27, 2016, number NCT02918214).</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Left ventricular diastolic dysfunction is prevalent but not associated with mortality in patients with septic shock

  • Philippe Vignon,
  • Cyril Charron,
  • Annick Legras,
  • Frédérique Musset,
  • Michel Slama,
  • Gwenaël Prat,
  • Stein Silva,
  • David Vandroux,
  • Grégoire Müller,
  • Bruno Levy,
  • Florence Boissier,
  • Bruno Evrard,
  • Marine Goudelin,
  • Stéfan Mankikian,
  • Mai-Anh NAY,
  • Julien Jabot,
  • Béatrice Riu,
  • Pierre Bailly,
  • Julien Maizel,
  • Julie Léger,
  • Antoine Vieillard-Baron

摘要

Purpose

Prognostic impact of left ventricular diastolic dysfunction (LVDD) in septic shock patients has not been determined using current diagnostic guidelines. We assessed the relation between LVDD during the first 3 days following intensive care unit (ICU) admission for septic shock and Day-28 mortality.

Methods

This prospective, multicenter, observational study enrolled 402 patients (age: 63 ± 13 year; 59% male; SAPS II: 59 ± 20; SOFA: 9.4 ± 3.6; mechanical ventilation: 74%) with septic shock (Sepsis-3 definition). Patients were echocardiographically assessed within 12 h after admission (Day 1), on Day 2, Day 3, at ICU and at hospital discharge (or Day 28 whichever occurred first), using 2016 American-European guidelines.

Results

LVDD was present at least once between Day 1 and 3 in 304 patients (76%), and in 56% and 44% of patients at ICU discharge and on Day 28 (or hospital discharge), respectively (43% of patients with follow-up). Seventy-eight of 172 patients (45%) exhibited similar LV diastolic properties throughout the study period while 58 patients (34%) improved their LVDD at follow-up (lower grade: n = 9, regression: n = 49). Day-28 mortality was not statistically different between patients with and without LVDD (80/304 [26%] vs. 25/88 [28%]; OR: 0.900 [0.530–1.527]; p = 0.696). Similar results were obtained when adjusting the multivariate model on SAPSII or SOFA score on admission, together with fluid balance during the first three days of ICU stay (OR: 0.838 [0.471–1.491]: p = 0.547 and OR: 0.887 [0.513–1.534]: p = 0.668, respectively).

Conclusion

LVDD was highly prevalent in patients with septic shock but not associated with mortality. It appeared improving in one-third of survivors.

Trial registration

PRODIASYS study registered on ClinicalTrials (September 27, 2016, number NCT02918214).